Signal from the log
SereNeuro Therapeutics
Pre-seed · United States
SereNeuro Therapeutics, à Baltimore, prépare SN101, des neurones humains de la douleur fabriqués à partir de cellules souches et injectés dans l'articulation pour calmer une douleur chronique sans opioïde. Pre-seed sans montant publié, auprès de deux fonds du Maryland non nommés.
Spotted Amount read from the headline
Announced on , logged by the watch of 5 October 2026.
- Operation
- Funding round
- Stage
- Pre-seed
- Country
- United States
What the log says
Editorial note, in French
Repérée par la collecte. Personne ne l'a encore instruite.
What is missing before publishing
- No fund is publicly named. It is the first condition of the selection bar: without a named investor there is no round to tell.
- No public amount. A missing amount is never estimated or inferred from a filing.
Provenance
Source prnewswire
Logged on 5 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification The fields shown come from an automatic reading of the source headline. They have not yet been checked against the press release and should not be quoted as verified.
What this status means
Spotted The collection saw this operation and logged it. Nobody has processed it yet, so what is shown is still an automatic reading of the source headline.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.